NYSE

Nu Skin Enterprises, Inc. (NUS)

371 Thanks from members

Nu Skin Enterprises, Inc. (NUS) reported mixed Q2 2026 results featuring in-line adjusted earnings of $0.20 per share but top-line revenue misses and a GAAP net loss driven by heavy impairment and tax valuation allowance charges.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →